BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
| Company type | Public |
|---|---|
Traded as |
|
| Industry | Biotechnology |
| Founded | March 1997 |
| Founders |
|
| Headquarters | San Rafael, California, U.S. |
Key people | |
| Products |
|
| Revenue | US$1.860 Billion (Fiscal Year Ended December 31, 2020) |
| –US$36.765 Million (Fiscal Year Ended December 31, 2020) | |
Net income | US$0.859 Billion (Fiscal Year Ended December 31, 2020) |
| Total assets | US$5.848 Billion (Fiscal Year Ended December 31, 2020) |
| Total equity | US$4.106 Billion (Fiscal Year Ended December 31, 2020) |
Number of employees | 2,581 (2017) |
| Website | biomarin |
| Footnotes / references | |
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.